These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Hypoxia imaging with Melsens E; De Vlieghere E; Descamps B; Vanhove C; Kersemans K; De Vos F; Goethals I; Brans B; De Wever O; Ceelen W; Pattyn P Radiat Oncol; 2018 Mar; 13(1):39. PubMed ID: 29514673 [TBL] [Abstract][Full Text] [Related]
5. Beyond detection: novel applications for PET imaging to guide cancer therapy. Rajendran JG; Mankoff DA J Nucl Med; 2007 Jun; 48(6):855-6. PubMed ID: 17536105 [No Abstract] [Full Text] [Related]
6. PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients. Bollineni VR; Kerner GS; Pruim J; Steenbakkers RJ; Wiegman EM; Koole MJ; de Groot EH; Willemsen AT; Luurtsema G; Widder J; Groen HJ; Langendijk JA J Nucl Med; 2013 Aug; 54(8):1175-80. PubMed ID: 23753185 [TBL] [Abstract][Full Text] [Related]
7. Imaging hypoxia in xenografted and murine tumors with 18F-fluoroazomycin arabinoside: a comparative study involving microPET, autoradiography, PO2-polarography, and fluorescence microscopy. Busk M; Horsman MR; Jakobsen S; Keiding S; van der Kogel AJ; Bussink J; Overgaard J Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1202-12. PubMed ID: 18313528 [TBL] [Abstract][Full Text] [Related]
8. Predictive value of (18)F-FAZA PET imaging for guiding the association of radiotherapy with nimorazole: a preclinical study. Tran LB; Bol A; Labar D; Cao-Pham TT; Jordan B; Grégoire V; Gallez B Radiother Oncol; 2015 Feb; 114(2):189-94. PubMed ID: 25616539 [TBL] [Abstract][Full Text] [Related]
9. PET hypoxia imaging with FAZA: reproducibility at baseline and during fractionated radiotherapy in tumour-bearing mice. Busk M; Mortensen LS; Nordsmark M; Overgaard J; Jakobsen S; Hansen KV; Theil J; Kallehauge JF; D'Andrea FP; Steiniche T; Horsman MR Eur J Nucl Med Mol Imaging; 2013 Jan; 40(2):186-97. PubMed ID: 23076620 [TBL] [Abstract][Full Text] [Related]
10. Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia. Blumenthal RD; Taylor A; Osorio L; Ochakovskaya R; Raleigh JA; Papadopoulou M; Bloomer WD; Goldenberg DM Int J Cancer; 2001 Nov; 94(4):564-71. PubMed ID: 11745445 [TBL] [Abstract][Full Text] [Related]
11. Comparison of 18F-fluoroazomycin-arabinofuranoside and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) in preclinical models of cancer. Valtorta S; Belloli S; Sanvito F; Masiello V; Di Grigoli G; Monterisi C; Fazio F; Picchio M; Moresco RM J Nucl Med; 2013 Jul; 54(7):1106-12. PubMed ID: 23699667 [TBL] [Abstract][Full Text] [Related]
12. Measurement of Tumor Hypoxia in Patients With Locally Advanced Cervical Cancer Using Positron Emission Tomography with Han K; Shek T; Vines D; Driscoll B; Fyles A; Jaffray D; Keller H; Metser U; Pintilie M; Xie J; Yeung I; Milosevic M Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):1202-1209. PubMed ID: 29680257 [TBL] [Abstract][Full Text] [Related]
13. Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA--first small animal PET results. Reischl G; Dorow DS; Cullinane C; Katsifis A; Roselt P; Binns D; Hicks RJ J Pharm Pharm Sci; 2007; 10(2):203-11. PubMed ID: 17706178 [TBL] [Abstract][Full Text] [Related]
14. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Grosu AL; Souvatzoglou M; Röper B; Dobritz M; Wiedenmann N; Jacob V; Wester HJ; Reischl G; Machulla HJ; Schwaiger M; Molls M; Piert M Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):541-51. PubMed ID: 17869667 [TBL] [Abstract][Full Text] [Related]
15. The hypoxic cytotoxin SR 4233 increases the effectiveness of radioimmunotherapy in mice with human non-Hodgkin's lymphoma xenografts. Wilder RB; McGann JK; Sutherland WR; Waller EK; Minchinton AI; Goris ML; Knox SJ Int J Radiat Oncol Biol Phys; 1994 Jan; 28(1):119-26. PubMed ID: 8270432 [TBL] [Abstract][Full Text] [Related]
16. Head and neck tumor hypoxia imaging by 18F-fluoroazomycin-arabinoside (18F-FAZA)-PET: a review. Halmos GB; Bruine de Bruin L; Langendijk JA; van der Laan BF; Pruim J; Steenbakkers RJ Clin Nucl Med; 2014 Jan; 39(1):44-8. PubMed ID: 24152663 [TBL] [Abstract][Full Text] [Related]
18. Tirapazamine administered as a neoadjuvant to radiotherapy reduces metastatic dissemination. Lunt SJ; Telfer BA; Fitzmaurice RJ; Stratford IJ; Williams KJ Clin Cancer Res; 2005 Jun; 11(11):4212-6. PubMed ID: 15930359 [TBL] [Abstract][Full Text] [Related]
19. Assessing hypoxia in animal tumor models based on pharmocokinetic analysis of dynamic FAZA PET. Busk M; Munk OL; Jakobsen S; Wang T; Skals M; Steiniche T; Horsman MR; Overgaard J Acta Oncol; 2010 Oct; 49(7):922-33. PubMed ID: 20831479 [TBL] [Abstract][Full Text] [Related]
20. A prospective clinical study of ¹⁸F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy. Servagi-Vernat S; Differding S; Hanin FX; Labar D; Bol A; Lee JA; Grégoire V Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1544-52. PubMed ID: 24570097 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]